REFERENCES
- Behçet H. Über rezidiverende aphtose, durch ein virus verursachte geschwüre am mund, am auge und an den genitalien. Dermatol Wochenschr 1937; 105: 1152–1157, [CSA]
- Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 1284, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Smith E L, Schur P H. Clinical manifestations and diagnosis of Behcet's disease. 2005, www.uptodateonline.com. UpToDate®
- Okada A A, Rao N A, Usui M. Behçet's disease. Ophthalmology, 2nd ed., M Yanoff, J S Duker. Mosby Inc. 2004
- Abreu M T, Bonfioli A A, Orefice F. Doenca de Behcet. Uveítes - Clínica e Cirúrgica. First Ed., F. Oréfice. Ed. Cultura Médica, Rio de Janeiro 2000; 843–859
- Barra C, Belfort R, Jr., Abreu M T, Kim M K, Martins M C, Petrilli A MN. Behcet's disease in Brazil: A review of 49 cases with emphasis on ophthalmic manifestations. Jpn J Ophthalmol 1991; 35: 339–346, [PUBMED], [INFOTRIEVE], [CSA]
- Kurokawa M S, Suzuki N. Behçet's disease. Clin Exp Med 2004; 3: 10–20, [CROSSREF], [CSA]
- Atmaca L S, Batioglu F. The efficacy of cyclosporin-A in the treatment of Behcet's disease. Ophthalmic Surg 1994; 25: 321, [PUBMED], [INFOTRIEVE], [CSA]
- Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: A single masked trial. Br J Ophthalmol 1992; 76: 241, [PUBMED], [INFOTRIEVE], [CSA]
- Whitcup S M, Salvo E C, Nussenblatt R B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994; 118: 39, [PUBMED], [INFOTRIEVE], [CSA]
- Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Behcet's disease. J Ocul Pharmacol 1994; 10: 553, [PUBMED], [INFOTRIEVE], [CSA]
- Sakane T, Tareno M. Novel approaches to Behcet's disease. Expert Opin Investig Drugs 2000; 9: 1993, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yazici H, Pazarli H, Barnes C G, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990; 322: 281, [PUBMED], [INFOTRIEVE], [CSA]
- Hamuryudan H, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome. Effects on long-term prognosis. Arthritis Rheum 1997; 40: 769, [PUBMED], [INFOTRIEVE], [CSA]
- Abdalla M I, el-D Bahoat N. Long-lasting remission of Behcet's disease after chlorambucil therapy. Br J Ophthalmol 1973; 57: 706, [PUBMED], [INFOTRIEVE], [CSA]
- O'Duffy J D, Robertson D M, Goldstein N P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984; 76: 75, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hamza M, Meddeb S, Mili I, Ouertani A. Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation. Ann Med Interne (Paris) 1992; 143: 438, [CSA]
- Pivetti-Pezzi P, Accorinti M, Pirraglia, et al. Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 1997; 75: 720, [PUBMED], [INFOTRIEVE], [CSA]
- Mochizuki M. Immunotherapy for Behcet's disease. Int Rev Immunol 1997; 14: 49, [PUBMED], [INFOTRIEVE], [CSA]
- Nichols J C, Ince A, Akduman L, Mann E S. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol 2001; 21: 109, [PUBMED], [INFOTRIEVE], [CSA]
- Zouboulis C C, Orfanos C E. Treament of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998; 134: 1010, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha-2b treatment in Behcet's syndrome. J Rheumatol 1994; 21: 1098, [PUBMED], [INFOTRIEVE], [CSA]
- Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138: 467, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kotter I, Zierhut M, Eckstein A K, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behcet's disease. J Am Acad Dermatol 1994; 31: 617, [PUBMED], [INFOTRIEVE], [CSA]
- O'Duffy J D, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behcet's disease. J Rheumatol 1998; 25: 1938, [PUBMED], [INFOTRIEVE], [CSA]
- Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004; 33: 320, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004; 33: 311, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kotter I, Zierhut M, Eckstein A K, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zouboulis C C, Orfanos C E. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998; 134: 1010, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gardner-Medwin J M, Smith N J, Powell R J. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828, [PUBMED], [INFOTRIEVE], [CSA]
- Jorizzo J L, White W L, Wise C M, et al. Low-dos weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behcet's disease. J Am Acad Dermatol 1991; 24: 973, [PUBMED], [INFOTRIEVE], [CSA]
- Sfikakis P P, Theodossiadis P G, Katsiari C G, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358: 295, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yasui K, Ohta K, Kobayashi M, et al. Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med 1996; 124: 891, [PUBMED], [INFOTRIEVE], [CSA]